<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04787471</url>
  </required_header>
  <id_info>
    <org_study_id>2021-001</org_study_id>
    <nct_id>NCT04787471</nct_id>
  </id_info>
  <brief_title>Corneal Crosslinking for Treatment of Corneal Neovascularization</brief_title>
  <official_title>Randomized Comparison of Standard vs. Accelerated Corneal Crosslinking for Treatment of Corneal Neovascularization With or Without Concomitant Inflammation and/or Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Price Vision Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cornea Research Foundation of America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Price Vision Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to assess safety and efficacy of photo-activation of riboflavin for&#xD;
      treatment of corneal neovascularization with or without concomitant inflammation and/or&#xD;
      infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2021</start_date>
  <completion_date type="Anticipated">July 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>corneal neovascularization as a proportion of the total corneal area</measure>
    <time_frame>6 months</time_frame>
    <description>the cornea will be photographed and morphometric image analysis software will be used to measure corneal neovascularization as a proportion of the total corneal area. The proportion measured at baseline will be compared with the proportion measured at 6 months after treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Corneal Neovascularization</condition>
  <arm_group>
    <arm_group_label>30 minute photoactivation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>photoactivation of riboflavin 0.1% using 365-nm UV light, 3mW/cm2 for 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 minute photoactivation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>photoactivation of riboflavin 0.1% using 365-nm UV light, 9mW/cm2 for 10 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>30 minute photoactivation of riboflavin 0.1%</intervention_name>
    <description>Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes</description>
    <arm_group_label>30 minute photoactivation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>10 minute photoactivation of riboflavin 0.1%</intervention_name>
    <description>Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes</description>
    <arm_group_label>10 minute photoactivation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  With active inflammation or infection causing vascularization and possibly melting of&#xD;
             the cornea, or vessels extending into the cornea causing lipid deposition, or&#xD;
             vascularization that could significantly increase the risk of rejection of a current&#xD;
             or planned corneal transplant, or vessels that continue to extend into the cornea&#xD;
             despite topical treatment with corticosteroids.&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known sensitivity to treatment medications&#xD;
&#xD;
          -  Current condition that in the investigator's opinion could compromise safety or data&#xD;
             integrity.&#xD;
&#xD;
          -  Pregnancy (including plan to become pregnant) or lactation during the course of the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis W Price, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Price Vision Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianne Price, PhD</last_name>
    <phone>317-814-2990</phone>
    <email>mprice@cornea.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Price, PhD</last_name>
      <phone>317-814-2990</phone>
      <email>mprice@cornea.org</email>
    </contact>
    <investigator>
      <last_name>Francis Price, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Feng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hersh PS, Stulting RD, Muller D, Durrie DS, Rajpal RK; U.S. Crosslinking Study Group. U.S. Multicenter Clinical Trial of Corneal Collagen Crosslinking for Treatment of Corneal Ectasia after Refractive Surgery. Ophthalmology. 2017 Oct;124(10):1475-1484. doi: 10.1016/j.ophtha.2017.05.036. Epub 2017 Jun 24.</citation>
    <PMID>28655538</PMID>
  </reference>
  <reference>
    <citation>Hersh PS, Stulting RD, Muller D, Durrie DS, Rajpal RK; United States Crosslinking Study Group. United States Multicenter Clinical Trial of Corneal Collagen Crosslinking for Keratoconus Treatment. Ophthalmology. 2017 Sep;124(9):1259-1270. doi: 10.1016/j.ophtha.2017.03.052. Epub 2017 May 7. Erratum in: Ophthalmology. 2017 Dec;124(12 ):1878.</citation>
    <PMID>28495149</PMID>
  </reference>
  <reference>
    <citation>Price MO, Fairchild K, Feng MT, Price FW Jr. Prospective Randomized Trial of Corneal Cross-linking Riboflavin Dosing Frequencies for Treatment of Keratoconus and Corneal Ectasia. Ophthalmology. 2018 Apr;125(4):505-511. doi: 10.1016/j.ophtha.2017.10.034. Epub 2017 Dec 2.</citation>
    <PMID>29203068</PMID>
  </reference>
  <reference>
    <citation>Price MO, Tenkman LR, Schrier A, Fairchild KM, Trokel SL, Price FW Jr. Photoactivated riboflavin treatment of infectious keratitis using collagen cross-linking technology. J Refract Surg. 2012 Oct;28(10):706-13. doi: 10.3928/1081597X-20120921-06.</citation>
    <PMID>23062001</PMID>
  </reference>
  <reference>
    <citation>Schaub F, Hou Y, Zhang W, Bock F, Hos D, Cursiefen C. Corneal Crosslinking to Regress Pathologic Corneal Neovascularization Before High-Risk Keratoplasty. Cornea. 2021 Feb 1;40(2):147-155. doi: 10.1097/ICO.0000000000002406.</citation>
    <PMID>33395116</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

